Truxima

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Truxima is used to treat Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Truxima is not chemotherapy, though it is sometimes used with chemotherapy treatment.

Truxima Overview

Reviewed: December 3, 2018
Updated: 

Truxima is a prescription medication used to treat certain Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

Truxima belongs to a group of drugs called monoclonal antibodies. Truxima is a CD20 antibody therapy. CD20 proteins live on the surface of cancer cells and some healthy blood cells. CD20 antibodies find and attack cancer cells by targeting and attaching to the CD20 proteins.

This medication is available in an injectable form to be given directly into a vein (IV) by a healthcare professional.

Common side effects include infusion-related reactions, infections, body aches, tiredness and nausea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Truxima Drug Class

Back to Top

Truxima is part of the drug class:

Truxima FDA Warning

Back to Top

WARNING: FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Infusion Reactions

Administration of rituximab products, including Truxima, can result in serious, including fatal, infusion reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Truxima infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions.

Severe Mucocutaneous Reactions

Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products.

Hepatitis B Virus (HBV) Reactivation

HBV reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Truxima. Discontinue Truxima and concomitant medications in the event of HBV reactivation.

Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products.